Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Priya Riyali, MBA 650-629-7900
clinicaltrials@recodetx.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF

A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF

Recruiting

Open to: ALL

Age: 18.0 - 65.0

Medical Conditions

Cystic Fibrosis
Fibrosis


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2024 Dec 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer

Intervention Arm Group : RCT2100 (Part 1);

Intervention Type : OTHER
Intervention Description : Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer

Intervention Arm Group : Placebo (Part 1);

Intervention Type : DRUG
Intervention Description : RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer for 4 weeks

Intervention Arm Group : RCT2100 (Part 2) 4 week;

Intervention Type : DRUG
Intervention Description : RCT2100 supplied at a single dose strength administered via oral inhalation using nebulizer for 12 weeks

Intervention Arm Group : RCT2100 (Part 2) 12 week;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • King's College Hospital
    London
  • University Hospital Southampton
    Southampton
  • Royal Papworth Hospital
    Cambridge
  • University Hospitals Birmingham
    Birmingham
  • Nottingham University Hospitals
    Nottingham
  • Leeds Teaching Hospitals
    Leeds


The study is sponsored by ReCode Therapeutics




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06237335
Last updated 04 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.